Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year

Journal of Experimental Medicine

Volumn 197, Issue 9, 2003, Pages 1065-1071

  Steinman, Lawrence ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID COPOLYMER; CHOLESTEROL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANIMAL MODEL; AUTOIMMUNITY; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DEMYELINATION; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL MODEL; HUMAN; IATROGENIC DISEASE; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; STARVATION; STRESS; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; MODELS, BIOLOGICAL; OPTIC NEURITIS;

EID: 0037882036     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030320     Document Type: Note

References (56)

1. Rivers, T.M., D.H. Sprunt, and G.P. Berry. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58:39-53.
2. Sriram, S., and L. Steinman. 1984. Postinfectious and post-vaccinial encephalomyelitis. In Neurology Clinics. Saunders, Philadelphia, 2:341-353.
3. Bettelli, E., M. Pagany, H.L. Weiner, C. Linington, R.A. Sobel, and V.K. Kuchroo. 2003. Myelin oligodendroglial glycoprotein TCR transgenic mice develop spontaneous optic neuritis. J. Exp. Med. 197:1073-1081.
4. Steinman, L. 2000. Multiple sclerosis: a two stage disease. Nat. Immunol. 2:762-764.
5. Pedotti, R., D. Mitchell, J. Wedemeyer, M. Karpuj, D. Chabas, E. Hattab, M. Tsai, S.J. Galli, and L. Steinman. 2001. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2:216-222.
6. Pedotti, R., J. DeVoss, S. Youssef, D. Mitchell, J. Wedemeyer, R. Madanat, H. Garren, P. Fontoura, M. Tsai, S.J. Galli, et al. 2003. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc. Natl. Acad. Sci. USA. 100:1867-1872.
7. Lafaille, J.J., F.V. Keere, A.L. Hsu, J. Baron, W. Hass, C.S. Raine, and S. Tonegawa. 1997. Myelin basic protein T helper 2 cells cause experimental autoimmune encephalomyelitis in immunodeficient mice rather than protect them from disease. J. Exp. Med. 186:307-312.
8. Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, et al. 2002. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
9. Chabas, D., S. Baranzini, D. Mitchell, C.C.A. Bernard, S. Rittling, D. Denhardt, R. Sobel, C. Lock, M. Karpuj, R. Pedotti, et al. 2001. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 294:1731-1735.
10. Ma, R.Z., J. Gao, N.D. Meeker, P.D. Fillmore, K.S. Tung, T. Watanabe, J.F. Zachary, H. Offner, E.P. Blankenhorn, and C. Teuscher. 2002. Identification of Bphs, an autoimmune disease locus, as histamine receptor H1. Science. 297: 620-623.
11. Secor, V.H., W.E. Secor, C.A. Gutekunst, and M.A. Brown. 2000. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191: 813-822.
12. Matarese, G., A.D. Giacomo, V. Sanna, G. Lord, J. Howard, A.D. Tuoro, S. Bloom, R. Lechler, S. Zappacosta, and S. Fontana. 2001. Requirement for leptin in induction and progression of experimental autoimmune encephalomyelitis. J. Immunol. 166:5909-5916.
13. Sanna, V., A. DiGiacomo, A. La Cava, R. Lechler, S. Fontana, S. Zappacosta, and G. Matarese. 2003. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J. Clin. Invest. 111:241-250.
14. Steinman, L., P. Conlon, R. Maki, and A. Foster. 2003. The intricate interplay among body weight, stress and the immune response to friend or foe. J. Clin. Invest. 111:183-185.
15. Poliak, S., F. Mor, P. Conlon, T. Wong, N. Ling, J. Rivier, W. Vale, and L. Steinman. 1997. Stress and autoimmunity: the neuropeptides corticotropin releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J. Immunol. 158:5751-5756.
16. Langer-Gould, A., H. Garren, A. Slansky, P.J. Ruiz, and L. Steinman. 2002. Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factor. J. Immunol. 169: 1084-1091.
17. Steinman, L., J.T. Rosenbaum, S. Sriram, and H.O. McDevitt. 1981. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. USA. 78:7111-7114.
18. Youssef, S., O. Stuve, J. Patorroyo, P. Ruiz, J. Radosevich, E.M. Hur, M. Bravo, D. Mitchell, R.A. Sobel, L. Steinman, and S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature. 420:78-84.
19. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242-248.
20. Yednock, T., C. Cannon, L. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 356:63-66.
21. von Adrian, U., and B. Engelhart. 2003. Alpha 4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. 348:68-72.
22. Robinson, W.H., C. DiGennaro, W. Hueber, B. Haab, M.' Kamachi, E. Dean, S. Fournel, D. Fong, M.C. Genovese, H. de Vegvar, et al. 2002. Antigen arrays for multiplex characterization of autoantibody responses. Nat. Med. 8:295-301.
23. Weiner, H.L. 2001. The fine line between autoimmune and allergic encephalomyelitis. Nat. Immunol. 2:193-194.
24. Bowern, N., I.A. Ramshaw, I.A. Clark, and P.C. Doherty. 1984. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J. Exp. Med. 160: 1532-1543.
25. Roach, A., K. Boylan, S. Horvath, S.B. Prusiner, and L.E. Hood. 1983. Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain of shiverer mutant mice. Cell. 34:799-806.
26. Kabat, E.A., A. Wolf, and A.L. Bezer. 1947. The rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J. Exp. Med. 85:117-129.
27. Arnason, B.G., B.D. Jankovic, B.H. Waksman, and L. Wennerstein. 1962. Role of the thumus in immune reactions in rats. II. Suppressive effect of thymectomy at birth on reactions of delayed (cellular) hypersensitivity and the circulating small lymphocyte. J. Exp. Med. 116:177-186.
28. Paterson, P.Y. 1960. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J. Exp. Med. 111:119-133.
29. Eylar, E.H., J. Salk, G.C. Beveridge, and L.V. Brown. 1969. Experimental allergic encephalonlyelitis. An encephalitogenic basic protein from bovine myelin. Arch. Biochem. Biophys. 132:34-48.
30. Ben-Nun, A., H. Wekerle, I.R. Cohen. 1981. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature. 292: 60-61.
31. Wraith, D.C., D.E. Smilek, DJ. Mitchell, L. Steinman, and H.O. McDevitt. 1989. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell. 59:247-255.
32. Sakai, K., DJ. Mitchell, SJ. Hodgkinson, S.S. Zamvil, J.B. Rothbard, and L. Steinman. 1989. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc. Natl. Acad. Sci. USA. 86:9470-9474.
33. Falk, K., O. Rotzschke, L. Santambrogio, M.E. Dorf, C. Brosnan, and J.L. Strominger. 2000. Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides. J. Exp. Med. 191:717-730.
34. Brostoff, S.W., and D.W. Mason. 1984. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J. Immunol. 133:1938-1942.
35. Waldor, M.K., R. Hardy, L.A. Herzenberg, L.A. Herzenberg, L. Lanier, S. Sriram, M. Lim, and L. Steinman. 1985. Reversal of EAE with monoclonal antibody to a T cell subset marker (L3T4). Science. 227:415-417.
36. Alters, S.E., K. Sakai, L. Steinman, and V.T. Oi. 1990. Mechanisms of anti-CD4 mediated depletion and immunotherapy: a study using a set of chimeric anti-CD4 antibodies. J. Immunol. 144:4587-4592.
37. Goverman, J., A. Woods, L. Larson, L.P. Weiner, L. Hood, and D.M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 72:551-560.
38. Baron, J.L., J.A. Madri, N.H. Ruddle, G. Hashim, and C.A. Janeway, Jr. 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57-68.
39. Baker, D., D. Butler, B.J. Scallon, J.K. O'Neill, J.L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24:2040-2048.
40. Lehmann, P.V., T. Forsthuber, A. Miller, and E.E. Sercarz. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:155-157.
41. Segal, B.M., J.T. Chang, and E.M. Shevach. 2000. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164: 5683-5688.
42. Jansson, M., V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor. 2002. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168:2096-2099.
43. Vandenbark, A.A., M. Vainiene, K. Ariail, S.D. Miller, and H. Offner. 1996. Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes. J. Neurosci. Res. 45:430-438.
44. Vandenbark, A.A., G. Hashim, and H. Offner. 1989. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature. 341:541-544.
45. Zhang, J. 2001. T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy. Crit. Rev. Immunol. 21:41-55.
46. Jyothi, M.D., R.A. Flavell, and T.L. Geiger. 2002. Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes. Nat. Biotechnol. 20:1215-1220.
47. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-534.
48. Genain, C.P., K. Abel, N. Belmar, F. Villinger, D.P. Rosenberg, C. Linington, C.S. Raine, and S.L. Hauser. 1996. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:2054-2057.
49. Bettadapura, J., K.K. Menon, S. Moritz, J. Liu, and C.C. Bernard. 1998. Expression, purification, and encephalitogenicity of recombinant human myelin oligodendrocyte glycoprotein. J. Neurochem. 70:1593-1599.
50. Smith, T., A. Groom, B. Zhu, and L. Turski. 2000. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6:62-66.
51. Pitt, D., P. Wemer, C.S. Raine. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:67-70.
52. Koh, D.R., W.P. Fung-Leung, A. Ho, D. Gray, H. Acha-Orbea, and T.W. Mak. 1992. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-mice. Science. 256:1210-1213.
53. Huseby, E.S., D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, and J. Goverman. 2001. A pathogenic role for myelin-specific CD8 (+) T cells in a model for multiple sclerosis. J. Exp. Med. 194:669-676.
54. Cua, D., J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:744-748.
55. Karin, N., D. Mitchell, N. Ling, S. Brocke, and L. Steinman. 1994. Reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of Interferon-γ and TNF-α production. J. Exp. Med. 180:2227-2237.
56. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, and P. Conlon. 2000. Steinman L and the APL in relapsing MS study group. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat. Med. 6:1176-1182.